Trials / Completed
CompletedNCT03426618
A Real-World Observational Study for the Safety and Efficacy of Baraclude in Korean Pediatric Patients With Chronic Hepatitis B
A Real-World Observational Study for the Safety and Efficacy of Baraclude (Entecavir) in Korean Pediatric (Aged 2-16 Years) Patients With Chronic Hepatitis B
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 2 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
This is a local, prospective observational study (regulatory post marketing surveillance) to access the safety and effectiveness of Baraclude in Korean pediatric patients with chronic HBV infection who are between the ages of 2 and less than 16 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Non-interventional | Non-interventional |
Timeline
- Start date
- 2018-01-12
- Primary completion
- 2019-03-13
- Completion
- 2019-03-13
- First posted
- 2018-02-08
- Last updated
- 2019-06-03
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03426618. Inclusion in this directory is not an endorsement.